Health Resource Utilization (HRU) and Costs for Metastatic Renal Cell Carcinoma (MRCC) Patients Treated With First-Line (1l) Systemic Therapy in The United States
Abstract
Authors
S Mhatre S Lin A Surinach R Vohra S Satram-Hoang J Simpson H Wallen S Ogale J Gong SK Pal DJ George